Literature DB >> 11724843

Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.

A Touzé1, S de Sanjosé, P Coursaget, M R Almirall, V Palacio, C J Meijer, J Kornegay, F X Bosch.   

Abstract

Genital human papillomavirus (HPV) infection is sexually transmitted. The aim of the study was to characterize serological responses to HPV types 16, 18, 31, and 58 by exploring type-specific virus-like particles (VLPs) in two groups of women with very distinct sexual behaviors. Anti-VLP antibodies for types 16, 18, 31, and 58 and HPV DNA in cervical cells were investigated with 177 prostitutes and 283 age-matched controls from the female general population in Spain. Anti-VLP positivity increased with number of lifetime sexual partners in women from the general population, and no seroresponse was found in virgins. However, in prostitutes HPV infection was characterized by higher multireactivity to three or four VLPs (25%) than the general population (3%) and by a more frequent antibody response to HPV-58 than in the general population. About 75% of the women seropositive for type 58 had been born in a Latin American country. Seroprevalence of HPV and cervical HPV DNA in prostitutes were 14 and 10 times higher than observed in women in the general population (prevalence odds ratio [POR] of HPV seropositivity, 14.04 [95%; CI = 8.4 to 23.6] and POR for HPV DNA, 10.4 [95% CI = 3.9 to 27.6). Our results indicate that prostitutes are at an increased risk of oncogenic HPV infections, and they confirm the validity of anti-VLPs as markers of present or past HPV infection, that the number of sexual partners is the major determinant in acquisition of oncogenic HPV, and that anti-VLPs could be used as a marker of repeated infection in prostitutes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724843      PMCID: PMC88547          DOI: 10.1128/JCM.39.12.4344-4348.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

1.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.

Authors:  A M de Roda Husman; J M Walboomers; A J van den Brule; C J Meijer; P J Snijders
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

2.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings.

Authors:  M V Jacobs; P J Snijders; A J van den Brule; T J Helmerhorst; C J Meijer; J M Walboomers
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study.

Authors:  A Andersson-Ellström; J Dillner; B Hagmar; J Schiller; M Sapp; L Forssman; I Milsom
Journal:  Sex Transm Dis       Date:  1996 May-Jun       Impact factor: 2.830

4.  Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix.

Authors:  K V Shah; R P Viscidi; A J Alberg; K J Helzlsouer; G W Comstock
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-04       Impact factor: 4.254

5.  The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.

Authors:  J J Carter; L A Koutsky; G C Wipf; N D Christensen; S K Lee; J Kuypers; N Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

6.  PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems.

Authors:  W Qu; G Jiang; Y Cruz; C J Chang; G Y Ho; R S Klein; R D Burk
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

7.  Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.

Authors:  R P Viscidi; K L Kotloff; B Clayman; K Russ; S Shapiro; K V Shah
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

8.  Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.

Authors:  T D de Gruijl; H J Bontkes; J M Walboomers; J T Schiller; M J Stukart; B S Groot; M M Chabaud; A J Remmink; R H Verheijen; T J Helmerhorst; C J Meijer; R J Scheper
Journal:  J Natl Cancer Inst       Date:  1997-05-07       Impact factor: 13.506

9.  In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

Authors:  W I White; S D Wilson; W Bonnez; R C Rose; S Koenig; J A Suzich
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.

Authors:  N D Christensen; J Dillner; C Eklund; J J Carter; G C Wipf; C A Reed; N M Cladel; D A Galloway
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

View more
  16 in total

1.  Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population.

Authors:  M Paz Cañadas; F Xavier Bosch; M Luisa Junquera; Maijo Ejarque; Rebeca Font; Elena Ordoñez; Silvia de Sanjosé
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers.

Authors:  Brandon Brown; Magaly Blas; Alejandra Cabral; Cesar Carcamo; Patti Gravitt; Neal Halsey
Journal:  Vaccine       Date:  2012-02-01       Impact factor: 3.641

3.  Higher prevalence of human papillomavirus infection in migrant women from Latin America in Spain.

Authors:  C González; M Ortiz; J Canals; L Muñoz; I Jarrín; M G de la Hera; A García-Saiz; J del Amo
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

Review 4.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

Review 5.  Oral Sex and HPV: Population Based Indications.

Authors:  Anupam Mishra; Veerendra Verma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-02-29

6.  Influence of age and geographical origin in the prevalence of high risk human papillomavirus in migrant female sex workers in Spain.

Authors:  J del Amo; C González; J Losana; P Clavo; L Muñoz; J Ballesteros; A García-Saiz; M J Belza; M Ortiz; B Menéndez; J del Romero; F Bolumar
Journal:  Sex Transm Infect       Date:  2005-02       Impact factor: 3.519

7.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

8.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

9.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients.

Authors:  Hala Badawi; Hanem Ahmed; Ahmed Ismail; Manal Diab; Magd Moubarak; Afkar Badawy; Mohamed Saber
Journal:  Medscape J Med       Date:  2008-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.